Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a performance beauty company with a promising outlook, as their two commercially available products - Jeuveau and Evolysse - continue to gain traction in the cash-pay aesthetic market. They are also well-positioned for competition against established players, such as Voluma and Galderma. Evolus's financials and long-term outlook are strong, with expected revenue growth and a solid pipeline. However, potential risks include a decrease in consumer spending and supply chain challenges.

Bears say

Evolus is a cash-pay medical company that specializes in aesthetic injectables such as Jeuveau and Evolysse, with a focus on targeting the millennial market. However, there are risks to their rating and price target such as potential competition, pricing pressure, and higher-than-expected operating expenses. Despite being an established brand with a 14% market share, concerns about consumer spending and commercial execution may negatively affect their growth potential in the near future.

Evolus (EOLS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Evolus (EOLS) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.